Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The study seeks to assess the response of glioblastoma multiforme to treatment using weekly low field (0.35 T) MR-images of the brain at a MRIdian® linac system during standard radiotherapy at the same system. A total of 20 patients in a single arm will be recruited for this investigation.
The imaging data will be used to evaluate the change in tumor volume over the course of the treatment and to perform radiomics in order to investigate the possibility of response prediction using these images.
In order to assure sufficient image quality, prior to the main investigation, a group of up to 20 volunteers has MR scans taken with identical sequences to the main study phase.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Low field (0.35 T) MR-images of the brain at a MRIdian® linac system | Device | Low field (0.35 T) MR-images of the brain at a MRIdian® linac system using CE marked low-field MR coils as provided by the company will be taken for volunteers in phase I. In phase II and III, after therapy beginning those images will be taken once per week per subject using CE marked low-field MR coils as provided by the company. This is done over the entire course of radiotherapy, which takes between 3 and 6 weeks. |
| Measure | Description | Time Frame |
|---|---|---|
| To assess target volume changes with MRI during fractionated MR-guided radiation therapy. | 6 Months |
| Measure | Description | Time Frame |
|---|---|---|
| Value of target changes with MRI during fractionated MR-guided radiation therapy | 6 Months |
Not provided
Inclusion criteria patients:
Subjects fulfilling all of the following criteria are eligible for the study:
Exclusion criteria
Not provided
Not provided
Not provided
Glioblastoma patients undergoing radio(chemo)therapy.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Michael Mayinger, MD | Contact | +41432530691 | michael.mayinger@usz.ch |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University Hospital Zurich | Recruiting | Zurich | Canton of Zurich | 8091 | Switzerland |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 41678045 | Derived | Wallimann P, Wild P, Martirosian P, Schick F, Mayinger M, Boss A, Bink A, Guckenberger M, Tanadini-Lang S, Andratschke N, Pouymayou B. Adaptation of an arterial spin labeling sequence for the assessment of brain perfusion on a 0.35 T MR-Linac. MAGMA. 2026 Feb 12. doi: 10.1007/s10334-026-01326-x. Online ahead of print. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D005909 | Glioblastoma |
| ID | Term |
|---|---|
| D001254 | Astrocytoma |
| D005910 | Glioma |
| D018302 | Neoplasms, Neuroepithelial |
| D017599 | Neuroectodermal Tumors |
Not provided
Not provided
Not provided
Not provided
Not provided
| D009373 |
| Neoplasms, Germ Cell and Embryonal |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D009375 | Neoplasms, Glandular and Epithelial |
| D009380 | Neoplasms, Nerve Tissue |